257 related articles for article (PubMed ID: 25631637)
1. An ATRActive future for differentiation therapy in AML.
Johnson DE; Redner RL
Blood Rev; 2015 Jul; 29(4):263-8. PubMed ID: 25631637
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.
van Gils N; Verhagen HJMP; Smit L
Exp Hematol; 2017 Aug; 52():12-23. PubMed ID: 28456748
[TBL] [Abstract][Full Text] [Related]
3. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.
Su M; Alonso S; Jones JW; Yu J; Kane MA; Jones RJ; Ghiaur G
PLoS One; 2015; 10(6):e0127790. PubMed ID: 26047326
[TBL] [Abstract][Full Text] [Related]
4. CDK2 suppression synergizes with all-trans-retinoic acid to overcome the myeloid differentiation blockade of AML cells.
Shao X; Xiang S; Fu H; Chen Y; Xu A; Liu Y; Qi X; Cao J; Zhu H; Yang B; He Q; Ying M
Pharmacol Res; 2020 Jan; 151():104545. PubMed ID: 31740384
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
Dembitz V; Lalic H; Tomic B; Smoljo T; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
Int J Hematol; 2022 Jan; 115(1):43-53. PubMed ID: 34546543
[TBL] [Abstract][Full Text] [Related]
6. Differentiation therapy of acute myeloid leukemia: past, present and future.
Petrie K; Zelent A; Waxman S
Curr Opin Hematol; 2009 Mar; 16(2):84-91. PubMed ID: 19468269
[TBL] [Abstract][Full Text] [Related]
7. Unlocking the potential of retinoic acid in anticancer therapy.
Schenk T; Stengel S; Zelent A
Br J Cancer; 2014 Nov; 111(11):2039-45. PubMed ID: 25412233
[TBL] [Abstract][Full Text] [Related]
8. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Apr; 10 Suppl 1():S12-5. PubMed ID: 8618462
[TBL] [Abstract][Full Text] [Related]
9. The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.
Shao X; Liu Y; Li Y; Xian M; Zhou Q; Yang B; Ying M; He Q
Sci Rep; 2016 Apr; 6():24589. PubMed ID: 27074819
[TBL] [Abstract][Full Text] [Related]
10. Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.
Zhang XW; Shen X; Long WY; Xiao H; Li FJ; Xing S; Xiong GL; Yu ZY; Cong YW
Int J Hematol; 2021 Feb; 113(2):254-262. PubMed ID: 33074481
[TBL] [Abstract][Full Text] [Related]
11. Targeting the SUMO Pathway Primes All-
Baik H; Boulanger M; Hosseini M; Kowalczyk J; Zaghdoudi S; Salem T; Sarry JE; Hicheri Y; Cartron G; Piechaczyk M; Bossis G
Cancer Res; 2018 May; 78(10):2601-2613. PubMed ID: 29487199
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
[TBL] [Abstract][Full Text] [Related]
13. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
14. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid and 6-formylindolo(3,2-b)carbazole (FICZ) combination therapy reveals putative targets for enhancing response in non-APL AML.
Bunaciu RP; MacDonald RJ; Jensen HA; Gao F; Wang X; Johnson L; Varner JD; Yen A
Leuk Lymphoma; 2019 Jul; 60(7):1697-1708. PubMed ID: 30570341
[TBL] [Abstract][Full Text] [Related]
16. Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.
Buteyn NJ; Fatehchand K; Santhanam R; Fang H; Dettorre GM; Gautam S; Harrington BK; Henderson SE; Merchand-Reyes G; Mo X; Benson DM; Carson WE; Vasu S; Byrd JC; Butchar JP; Tridandapani S
Int Immunol; 2018 Jul; 30(8):375-383. PubMed ID: 29868798
[TBL] [Abstract][Full Text] [Related]
17. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship.
Agadir A; Cornic M; Lefebvre P; Gourmel B; Jérôme M; Degos L; Fenaux P; Chomienne C
J Clin Oncol; 1995 Oct; 13(10):2517-23. PubMed ID: 7595702
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
19. All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype.
Chen Z; Wang Y; Wang W; Gong J; Xue Y
Chin Med J (Engl); 2002 Jan; 115(1):58-61. PubMed ID: 11930660
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.
Fang Y; Zhou X; Lin M; Ying M; Luo P; Zhu D; Lou J; Yang B; He Q
Mol Carcinog; 2011 Jan; 50(1):24-35. PubMed ID: 20945414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
